Akèy › Limfòm Burkitt › Alabama
Etid klinik pou Limfòm Burkitt nan Alabama
7 etid pou Limfòm Burkitt ap chèche patisipan nan sit nan Alabama.
Vil nan Alabama
Tèks ofisyèl etid la (Anglè)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Hospital of Alabama, Birmingham
Ap rekriteFaz 2
366 Days – 46 Years · Tout sèks · Mizajou Oct 2, 2026 · NCT06124157Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Children's Hospital of Alabama, Birmingham
Ap rekriteFaz 2
365 Days · Tout sèks · Mizajou Sep 25, 2026 · NCT06317662A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Hospital of Alabama, Birmingham
- USA Health Strada Patient Care Center, Mobile
Ap rekriteFaz 2
Laj 1 a 30 · Tout sèks · Mizajou Sep 1, 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Children's Hospital of Alabama, Birmingham
- USA Health Strada Patient Care Center, Mobile
Ap rekriteFaz 3
365 Days – 25 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT03959085Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- University of Alabama at Birmingham, Birmingham
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Nov 5, 2025 · NCT04260022The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- Children's of Alabama/University of Alabama in Birmingham(UAB), Birmingham
Ap rekriteFaz 2
Laj 1 a 25 · Tout sèks · Mizajou May 4, 2025 · NCT03509961Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
- University of Alabama at Birmingham, Birmingham
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Nov 15, 2024 · NCT06034275Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.